Nektar Therapeutics (NASDAQ: NKTR) today announced that it has commenced dosing patients with systemic lupus erythematosus (SLE) in a Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE